Junyuan Qi
YOU?
Author Swipe
View article: Liposomal mitoxantrone monotherapy in patients with relapsed or refractory mature T‐cell and natural killer‐cell neoplasms: A phase 2, multicenter, open‐label, single‐arm trial
Liposomal mitoxantrone monotherapy in patients with relapsed or refractory mature T‐cell and natural killer‐cell neoplasms: A phase 2, multicenter, open‐label, single‐arm trial Open
Introduction The prognosis of relapsed or refractory mature T‐ and natural killer (NK)‐cell lymphoma remains dismal. Novel agents are urgently needed to improve the outcomes for this population. Methods In this phase 2, multicenter, open‐l…
View article: Phase 1 study of isatuximab monotherapy in Chinese patients with relapsed/refractory multiple myeloma
Phase 1 study of isatuximab monotherapy in Chinese patients with relapsed/refractory multiple myeloma Open
In this multi-center, Phase-1 study (NCT03733717), we characterized the pharmacokinetics (PK) of the anti-CD38 antibody isatuximab (Isa) after IV administration (primary objective), and evaluated safety, immunogenicity, and preliminary ant…
View article: Patients with acquired pure red cell aplasia respond to <scp>PI3Kδ</scp> inhibitor rapidly
Patients with acquired pure red cell aplasia respond to <span>PI3Kδ</span> inhibitor rapidly Open
Pure red cell aplasia (PRCA) is a rare disease for which large controlled trials are challenging and as such recommendations are mostly based on retrospective studies or case accumulations. Cyclosporine A (CsA) provides the most effective …
View article: Safety and Pharmacokinetics of Quizartinib Combination Therapy With Standard Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia: Results from Two Phase 1 Trials in Japan and China
Safety and Pharmacokinetics of Quizartinib Combination Therapy With Standard Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia: Results from Two Phase 1 Trials in Japan and China Open
Quizartinib is a potent, oral, second‐generation, selective type II FMS‐like receptor tyrosine kinase 3 (FLT3) inhibitor. It has shown improved overall survival in a randomized, multinational, Phase 3 (QuANTUM‐First) study in patients with…
View article: Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors
Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors Open
Sovleplenib (HMPL-523) is a selective spleen tyrosine kinase (Syk) inhibitor with antitumor activity in preclinical models of B-cell malignancy. We conducted a dose-escalation and dose-expansion phase I study of sovleplenib in patients wit…
View article: P635: AN UPDATE OF SAFETY AND EFFICACY RESULTS FROM PHASE 1 STUDY OF LP-108, A NOVEL AND SELECTIVE BCL-2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMAS
P635: AN UPDATE OF SAFETY AND EFFICACY RESULTS FROM PHASE 1 STUDY OF LP-108, A NOVEL AND SELECTIVE BCL-2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMAS Open
Background: The effectiveness of BCL-2 inhibition in hematologic malignancies has been demonstrated by venetoclax, a globally approved BCL-2 inhibitor that requires weekly dose ramp-up to mitigate the risk of tumor lysis syndrome (TLS) and…
View article: Table S1 from The Impact of Clone Size on the Prognostic Value of Chromosome Aberrations by Fluorescence <i>In Situ</i> Hybridization in Multiple Myeloma
Table S1 from The Impact of Clone Size on the Prognostic Value of Chromosome Aberrations by Fluorescence <i>In Situ</i> Hybridization in Multiple Myeloma Open
Table S1. The distribution of cytogenetics by probes in positive group.
View article: Figure S1 from The Impact of Clone Size on the Prognostic Value of Chromosome Aberrations by Fluorescence <i>In Situ</i> Hybridization in Multiple Myeloma
Figure S1 from The Impact of Clone Size on the Prognostic Value of Chromosome Aberrations by Fluorescence <i>In Situ</i> Hybridization in Multiple Myeloma Open
Figure S1. ROC curve for the relation of cytogenetic abnormalities and progression or survival in MM patients.
View article: Table S1 from The Impact of Clone Size on the Prognostic Value of Chromosome Aberrations by Fluorescence <i>In Situ</i> Hybridization in Multiple Myeloma
Table S1 from The Impact of Clone Size on the Prognostic Value of Chromosome Aberrations by Fluorescence <i>In Situ</i> Hybridization in Multiple Myeloma Open
Table S1. The distribution of cytogenetics by probes in positive group.
View article: Data from The Impact of Clone Size on the Prognostic Value of Chromosome Aberrations by Fluorescence <i>In Situ</i> Hybridization in Multiple Myeloma
Data from The Impact of Clone Size on the Prognostic Value of Chromosome Aberrations by Fluorescence <i>In Situ</i> Hybridization in Multiple Myeloma Open
Purpose: Accumulating evidence indicates that intratumor heterogeneity is prevalent in multiple myeloma and that a collection of multiple, genetically distinct subclones are present within the myeloma cell population. It is not clea…
View article: Data from The Impact of Clone Size on the Prognostic Value of Chromosome Aberrations by Fluorescence <i>In Situ</i> Hybridization in Multiple Myeloma
Data from The Impact of Clone Size on the Prognostic Value of Chromosome Aberrations by Fluorescence <i>In Situ</i> Hybridization in Multiple Myeloma Open
Purpose: Accumulating evidence indicates that intratumor heterogeneity is prevalent in multiple myeloma and that a collection of multiple, genetically distinct subclones are present within the myeloma cell population. It is not clea…
View article: Figure S1 from The Impact of Clone Size on the Prognostic Value of Chromosome Aberrations by Fluorescence <i>In Situ</i> Hybridization in Multiple Myeloma
Figure S1 from The Impact of Clone Size on the Prognostic Value of Chromosome Aberrations by Fluorescence <i>In Situ</i> Hybridization in Multiple Myeloma Open
Figure S1. ROC curve for the relation of cytogenetic abnormalities and progression or survival in MM patients.
View article: Pharmacokinetics of single- and multiple-dose flumatinib in patients with chronic phase chronic myeloid leukemia
Pharmacokinetics of single- and multiple-dose flumatinib in patients with chronic phase chronic myeloid leukemia Open
Introduction Flumatinib is a novel, oral breakpoint cluster region-abelson (BCR-ABL) tyrosine kinase inhibitor that has demonstrated manageable safety and promising efficacy in patients with newly diagnosed chronic phase (CP) chronic myelo…
View article: Safety and efficacy of daratumumab in Chinese patients with relapsed or refractory multiple myeloma: a phase 1, dose-escalation study (MMY1003)
Safety and efficacy of daratumumab in Chinese patients with relapsed or refractory multiple myeloma: a phase 1, dose-escalation study (MMY1003) Open
View article: A two‐part, single‐arm, multicentre, phase I study of zanubrutinib, a selective <scp>Bruton tyrosine kinase</scp> inhibitor, in Chinese patients with relapsed/refractory B‐cell malignancies
A two‐part, single‐arm, multicentre, phase I study of zanubrutinib, a selective <span>Bruton tyrosine kinase</span> inhibitor, in Chinese patients with relapsed/refractory B‐cell malignancies Open
Summary This single‐arm, multicentre, phase I study is the first study of zanubrutinib, a potent, specific, irreversible Bruton tyrosine kinase (BTK) inhibitor, in Chinese patients with relapsed/refractory B‐cell malignancies. The objectiv…
View article: Efficacy and safety of GLS-010 (zimberelimab) in patients with relapsed or refractory classical Hodgkin lymphoma: A multicenter, single-arm, phase II study
Efficacy and safety of GLS-010 (zimberelimab) in patients with relapsed or refractory classical Hodgkin lymphoma: A multicenter, single-arm, phase II study Open
GLS-010 (zimberelimab) appears to be effective and safe for the treatment of Chinese patients with r/r-cHL. Long-term follow-up is required to confirm these clinical benefits.
View article: Phase 1 clinical trial of the PI3Kδ inhibitor YY-20394 in patients with B-cell hematological malignancies
Phase 1 clinical trial of the PI3Kδ inhibitor YY-20394 in patients with B-cell hematological malignancies Open
View article: Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphoma
Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphoma Open
GLS-010 showed acceptable safety profile and favorable clinical response. The dose of 240 mg Q2W was an optimal recommended dose as monotherapy.
View article: Pharmacokinetics and safety of IBI301 versus rituximab in patients with CD20+ B-cell lymphoma: a multicenter, randomized, double-blind, parallel-controlled study
Pharmacokinetics and safety of IBI301 versus rituximab in patients with CD20+ B-cell lymphoma: a multicenter, randomized, double-blind, parallel-controlled study Open
This multicenter, randomized, double-blind, parallel-controlled trial aimed to compare the pharmacokinetics (PK) of IBI301 with rituximab in patients with CD20-positive (CD20 + ) B-cell lymphoma, who achieved a complete response/unconfirme…
View article: [Clinical features and genetic manifestations of two families with Gaucher's disease].
[Clinical features and genetic manifestations of two families with Gaucher's disease]. Open
View article: High incidence of MYC and BCL2 abnormalities in mantle cell lymphoma, although only MYC abnormality predicts poor survival
High incidence of MYC and BCL2 abnormalities in mantle cell lymphoma, although only MYC abnormality predicts poor survival Open
The incidence and prognostic role of MYC and BCL2 rearrangements in mature B-cell lymphomas have been extensively studied, except the infrequent mantle cell lymphoma (MCL). Here, we analyzed the MYC and BCL2 abnormalities and other cytogen…
View article: Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China
Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China Open
Our results demonstrate the superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in Chinese cohort with newly diagnosed B-iNHLs and further identify subpopulations that are more sensitive to R-based chemoimmunother…
View article: [Clinical and biological characteristics of non-IgM lymphoplasmacytic lymphoma].
[Clinical and biological characteristics of non-IgM lymphoplasmacytic lymphoma]. Open
The clinical and biological characteristics had no significantly difference between non-IgM LPL and WM.
View article: [Clinical analysis of multiple myeloma patients with bone-related extramedullary disease: a longitudinal study on 834 consecutive patients in a single center of China].
[Clinical analysis of multiple myeloma patients with bone-related extramedullary disease: a longitudinal study on 834 consecutive patients in a single center of China]. Open
The clinical features of MM patients with bEMD are different from the patients with sEMD. Outcomes of this population is significantly better than the latter, and is comparable to the patients without EMD. It suggests that bEMD alone has n…
View article: [Clinical analysis of 25 patients with aggressive peripheral T-cell lymphoma in advanced stage treated with autologous stem cell transplantation].
[Clinical analysis of 25 patients with aggressive peripheral T-cell lymphoma in advanced stage treated with autologous stem cell transplantation]. Open
ASCT could improve the survival of aggressive PTCLs. Non CR1 status and bone marrow involvement had negative influence on OS in patients with aggressive PTCLs treated by ASCT. The prognosis was very poor in patients with HSTL and satisfact…